| Literature DB >> 32551015 |
James R Hill1,2, Xia Shao2, Jay S Wright2, Jenelle Stauff2, Phillip S Sherman2, Janna Arteaga2, Ka Kit Wong2, Benjamin L Viglianti2,3, Peter J H Scott2, Allen F Brooks2.
Abstract
PD-132301, an inhibitor of sterol O-acyltransferase 1 (SOAT1; also known as acyl-coenzyme A:cholesterol acyltransferase-1, ACAT1), is under clinical investigation for numerous adrenal disorders. Radiolabeled SOAT1 inhibitors could support drug discovery and help diagnose SOAT1-related disorders, such as atherosclerosis. We synthesized two radiolabeled SOAT1 inhibitors, [11C]PD-132301 and fluorine analogue [18F]1. Rat biodistribution studies were conducted with both agents and, as the most selective tracer, [11C]PD-132301 was advanced to preclinical positron emission tomography studies in (atherosclerotic) ApoE-/- mice. The uptake of [11C]PD-132301 in SOAT1-rich tissue warrants further investigation into the compound as an atherosclerosis and adrenal imaging agent.Entities:
Year: 2020 PMID: 32551015 PMCID: PMC7294710 DOI: 10.1021/acsmedchemlett.0c00127
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345